Teva Recalls Risedronate Sodium Tablets Due to Dissolution Failures
Teva Pharmaceuticals is recalling Risedronate Sodium Delayed-release Tablets because stability testing revealed low out-of-specification dissolution results.
- Product
- Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.
- Category
- Drug
- Distribution
- Distributed nationwide